CLEVELAND, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the Biotech Showcase™ 2015 to be held on January 12-14, 2015 in San Francisco, California, at the Parc 55 Wyndham San Francisco – Union Square.
William (B.J.) Lehmann, President and Chief Operating Officer, will present on Tuesday, January 13, 2015 at 11:00 a.m. Pacific Standard Time.
Biotech Showcase is an investor conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to meet with investors and pharmaceutical executives, who will discuss the latest in healthcare innovation. This annual gathering of the industry is widely viewed as setting the tone for the coming year, and the presenting companies represent some of the most innovative companies ranging from discovery through commercialization stage companies across the biopharmaceutical specialty market.
To listen to the live audio webcast of the presentation during the event, please visit: www.athersys.com. A replay of the webcast will be available for 30 days after the initial presentation.
About Athersys
Athersys is a clinical stage biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product platform for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas. The Company currently has several clinical stage programs involving MultiStem, including for treating inflammatory bowel disease, ischemic stroke, damage caused by myocardial infarction, and for the prevention of graft-versus-host disease. Athersys has also developed a diverse portfolio that includes other technologies and product development opportunities, and has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products.